Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3770 Molecular imaging, molecular profiling and outcomes in patients with transformation to grade 3 neuroendocrine neoplasia (NEN)

Introduction: Transformation of Grade (G) 1-2 to G3 NEN has prognostic & therapeutic implications, but its mechanisms are unclear.

Conference:

Presenting Author: Kong G

Authors: Kong G, Prall O, Flynn A, Tothill R, Hatzimihalis A,

Keywords: G3, transformation, IHC, genomic sequencing, FDG PET/CT, P53, Rb1, mutations,

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,

#3443 Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy

Introduction: Non-invasive tools to improve prognostication are warranted in patients with neuroendocrine neoplasms (NEN). Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome, but largely unknown in NEN. uPAR-targeted radionuclide therapy has proven effective in preclinical models and uPAR may be a potential target in NEN patients.

Conference:

Presenting Author: Carlsen E

Authors: Carlsen E, Loft M, Loft A, Berthelsen A, Langer S,

Keywords: urokinase plasminogen activator receptor (upar), neuroendocrine neoplasm, pet, prognosis, molecular imaging,

#3432 Fibroblast Activation Protein (FAP)-directed molecular imaging segregates between subtypes of poorly differentiated neuroendocrine neoplasms

Introduction: Fibroblast activation protein (FAP) is overexpressed in highly aggressive gastroenteropancreatic neuroendocrine neoplasms (NEN).

Conference:

Presenting Author: Weich A

Authors: Weich A, Wild V, Higuchi T, Meining A, Rowe S,

Keywords: [68Ga]FAPI, fibroblast activation protein, neuroendocrine, molecular imaging, ert,

#3161 Phase 1 trial of PARP inhibitor combined with 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastatic neuroendocrine tumor - PARLuNET

Introduction: 177Lu-DOTA-Octreotate (177Lu-DOTATATE) is an effective treatment for patients with grade 1 and 2 NET. However, strategies are required to optimize treatment efficacy and outcomes. Combining a DNA-repair modifying agent could further enhance radiation efficacy. Pre-clinical data supports that a PARP inhibitor (PARPi) combined with PRRT significantly enhances NET cell death and animal survival compared to 177Lu-DOTATATE alone. This combination strategy aims to enhance radiation efficacy from PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Hatzimihalis A, Hogg A, Bressel M, Hicks R,

Keywords: PRRT, PARP inhibitor, combination therapy, NET, pancreatic, phase 1,